Abstracts tagged "Antibodies"

Abstract Number: 1858 • 2015 ACR/ARHP Annual Meeting
Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients
Kathleen Borghoff¹, Andy Hollins², Michael J. Duryee¹, Ted R. Mikuls², Zhixin Zhang³, Kaihong Su⁴, Michelene Hearth-Holmes⁵ and Geoffrey M. Thiele⁶, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁴Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous studies have shown that patients with systemic lupus erythematosus (SLE) are prone to systemic osteoporosis, bone loss and fracture. Paradoxically, previous studies…
Abstract Number: 2019 • 2015 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammatory Arthritis in First Degree Relatives of Patients with Rheumatoid Arthritis and Their Association with Lifestyle Risk Factors
Jamie C Sergeant and RA-MAP Consortium, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) and C-reactive protein (CRP) are known serum biomarkers of inflammatory arthritis (IA) and have potential predictive…
Abstract Number: 2057 • 2015 ACR/ARHP Annual Meeting
Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars
Begoña Ruiz-Argüello¹, Ainara Maguregui¹, Ainhoa Ruiz del Agua¹, Dora Pascual-Salcedo², Ana Martínez², Teresa Jurado³, Chamaida Plasencia⁴, Alejandro Balsa⁵, Francisca Llinares-Tello⁶, José Rosas⁷, Nerea Torres¹, Antonio Martínez¹ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁶Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain
Background/Purpose: Infliximab (IFX) is the most immunogenic of anti-TNFα drugs available to treat patients with rheumatic diseases. The recent approval of the first infliximab biosimilars in…
Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting
Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Jutta Bauhammer¹, Norbert Blank², Hanns-Martin Lorenz³, Regina Max⁴, Dietmar Krause⁵ and Christoph Fiehn¹, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁴Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁵Dept. of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…
Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Thaschawee Arkachaisri^1,2, Justin Hung Tiong Tan¹, Manasita Tanya¹, Sook Fun Hoh³, Lena Das⁴ and Jing Yao Leong^5,6, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁵Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ⁶SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…
Abstract Number: 2367 • 2015 ACR/ARHP Annual Meeting
Risk of Malignancy in Dermatomyositis with Anti-CADM-140/ Melanoma Differentiation- Associated Gene 5 Autoantibody
Shinji Sato¹, Takayoshi Kurabayashi¹, Sho Sasaki², Yasushi Koyama², Shinichi Nogi³, Naofumi Chinen¹, Chiho Yamada¹ and Yasuo Suzuki¹, ¹Internal Medicine/ Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Internal Medicine/Rheumatology, Tokai University School of Medicine, Isehara, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Anti-CADM-140/ Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM)…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 2771 • 2014 ACR/ARHP Annual Meeting
PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica
Niklas Thomas Baerlecken¹, Torsten Witte², Marco Amedeo Cimmino³ and Dario Camellino⁴, ¹Clinical Immunology and Rheumatology, MD, Hannover, Germany, ²Medical School Hannover, MD, Hanover, Germany, ³Clinica Reumatologica, Università di Genova, Genova, Italy, ⁴Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy
Background/Purpose Previously we described antibodies against ferritin heavy chain peptide (anti-FHCP) in sera of patients with giant cell arteritis (GCA) and/or polymyalgia rheumatic (PMR) before…
Abstract Number: 2663 • 2014 ACR/ARHP Annual Meeting
Sense of Smell, Anti-Ribosomal P Antibodies and Neuropsychiatric Manifestations in Systemic Lupus Erythematosus
Fernando Augusto Peres¹, Karina Oliveira Peliçari², Nailu A. Sinicato¹, Mariana Postal¹, Aline T. Lapa¹, Lilian Costallat³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²State University of Campinas, Campinas, Brazil, ³Medicine, State University of Campinas, Campinas, United Kingdom, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose Neuropsychiatric manifestations occur in 12-95% of SLE patients. Recent studies have demonstrated the high specificity of antiribosomal P antibodies for SLE. Antiribosomal P antibodies…
Abstract Number: 2652 • 2014 ACR/ARHP Annual Meeting
Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies
Anne B Tjensvoll¹, Maria B Lauvsnes², Shunsei Hirohata³, Jan T Kvaløy⁴, Mona K Beyer⁵, Erna Harboe⁶, Lasse G Gøransson⁶, Ole J Greve⁷ and Roald Omdal⁸, ¹Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ²Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁴Research Department, Stavanger University Hospital, Stavanger, Norway, ⁵Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ⁶Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁷Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Headache, especially migraine, is frequent and one of the most common neuropsychiatric manifestations in systemic lupus erythematosus (SLE). A possible mechanism for this is…
Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting
Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Alan N. Baer¹, Michelle Petri², David Fiorentino³, Tao Wang⁴, Jungsan Sohn⁴, Antony Rosen¹ and Livia Casciola-Rosen⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…
Abstract Number: 2350 • 2014 ACR/ARHP Annual Meeting
A Humanized Monoclonal Antibody Raised Against a Heat Shock Protein Epitope Suppresses Autoimmune Inflammatory Diseases By Skewing the Immune System Selectively Towards an Anti-Inflammatory Response
Yaakov Naparstek¹, Rina Ulmansky², Galia Katzavian³, Ronit Meyuhas³, Eli Moallem⁴, Shira Yair³, Dorit Landstein³ and Virginie Loeb³, ¹Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ²Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ³ProtAb Ltd., Jerusalem, Israel, ⁴Dept. of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Background/Purpose We have previously shown that resistance to Adjuvant Arthritis (AA) is due to the presence of anti-heat shock protein (HSP) antibodies, directed at peptide-6,…
Abstract Number: 2008 • 2014 ACR/ARHP Annual Meeting
Personalized Risk Education for Rheumatoid Arthritis Improves Self-Perceived Risk Accuracy and Risk Factor Knowledge in First-Degree Relatives
Jeffrey A. Sparks¹, Maura D. Iversen^1,2,3, Rachel Miller Kroouze^1,4, Nellie A. Triedman¹, Taysir G. Mahmoud¹, Sarah S. Kalia⁴, Michael L. Atkinson⁵, Robert C. Green⁴ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Physical Therapy, Movement & Rehabilitation Sciences, Northeastern University, Boston, MA, ³Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Having a first-degree relative (FDR) with RA increases personal RA risk by four-fold. Other RA risk factors include demographics, genetics, auto-antibodies, and behaviors. We…
Abstract Number: 1703 • 2014 ACR/ARHP Annual Meeting
An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma
Cosimo Bruni¹, Ana Lages², Hitesh Patel³, Jennifer Harvey³, Voon H. Ong⁴, Marco Matucci-Cerinic¹, Emma C. Derrett-Smith⁵ and Christopher P Denton⁶, ¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²Affiliation servicio de Medicina Interna, Hospital De Braga, Braga, Portugal, ³Department of Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom
Association of anti-PM/Scl antibody with risk of malignancy in scleroderma. C. Bruni¹, A. Lages², H. Patel3, J. Harvey3, V. Ong4, M. Matucci-Cerinic¹, E. Derrett-Smith4, C.P.…
Abstract Number: 1620 • 2014 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)
Andy Hollins¹, Michael Duryee², Michelene Hearth-Holmes³, Ted R. Mikuls¹, Zhixin Zhang⁴, Kaihong Su⁵ and Geoffrey M. Thiele⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose Studies have shown that malondialdehyde-acetaldehyde (MAA) is formed as a result of lipid peroxidation of cellular membranes and is capable of binding or adducting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].